ProKidney Corp. (PROK) stock
PROKNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$1.04−0.10 (-9.13%)
Close on Nov 13, 2026Market cap $315.93MP/E –Yield –
Earnings
ProKidney's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Mar 17, 2027
Q4 FY2026 · estimated, during market hours
Revenue, Q2 FY2026
$150.00K
-32.1% on a year earlier
EPS, Q2 FY2026
-$0.15
-$0.13 a year earlier
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of ProKidney's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Mar 17, 2027Expected | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 12, 2026after the close | – | – | – | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 10, 2026during market hours | $150.00K | -32.1% | -$0.15 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 15, 2026before the open | $226.00K | -1.7% | -$0.14 | Release |
| Q4 FY2025ended Dec 31, 2025 | Mar 18, 2026during market hours | – | – | – | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 10, 2025during market hours | $217.00K | – | -$0.12 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 12, 2025during market hours | $221.00K | – | -$0.13 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 12, 2025during market hours | $230.00K | – | -$0.13 | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 17, 2025during market hours | – | – | – | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 12, 2024before the open | – | – | -$0.14 | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 9, 2024before the open | – | – | -$0.16 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 10, 2024before the open | – | – | -$0.16 | Release |
| Q4 FY2023ended Dec 31, 2023 | Mar 22, 2024after the close | – | – | – | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 14, 2023before the open | – | – | -$0.18 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 10, 2023during market hours | – | – | -$0.14 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 11, 2023during market hours | – | – | -$0.16 | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 28, 2023during market hours | – | – | -$0.11 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 14, 2022before the open | – | – | -$0.13 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 12, 2022during market hours | – | – | -$0.12 | Release |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
ProKidney has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When ProKidney puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases ProKidney filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Results
- Update
- Update
- Results
- ProKidney Reports Second Quarter 2025 Financial Results and Provides Regulatory and Clinical UpdatesResults
- Update
- Update
- Update
- Update
- Update
See a number that looks wrong?